NipentExtraAlternative Names: PentoExtra; Pentostatin - SuperGen
Latest Information Update: 16 Nov 2006
At a glance
- Originator SuperGen
- Mechanism of Action Adenosine deaminase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hairy cell leukaemia
Most Recent Events
- 25 Jan 1999 PentoExtra is now called NipentExtra
- 08 May 1998 Preclinical development for Hairy cell leukaemia in USA (Unknown route)